Gastrointestinal Cancer News

The National Institute for Health and Care Excellence released a Medtech Innovation Briefing stating SIR-Spheres ytrrium-90 resin microspheres may be used as an alternative to standard therapy for the treatment of patients with inoperable primary hepatocellular carcinoma, according to a press release from the manufacturer.

Clinical Genomics closed a $15 million Series A financing round, and will use the funding to commercialize its two-gene blood test for monitoring colorectal cancer recurrence after surgery, according to a press release.

Hepatocellular carcinoma incidence in Melbourne, Australia was twofold higher compared with reports found in the Victoria Cancer Registry — a population-based registry that includes the population of Melbourne — suggesting hepatocellular carcinoma is underreported in this region, according to data published in Hepatology.

Jean-Yves Douillard, MD, PhD, has been named the European Society for Medical Oncology’s first chief medical officer.

Physician density in relation to geographic concentration was not associated with the likelihood of receiving radiation therapy, results showed.

Patients with cancer who died at home experienced similar or significantly longer time until death than those who died in a hospital, according to results of a prospective cohort study conducted in Japan.

A new center at University of California, San Francisco, is designed to provide comprehensive and integrated care for patients with cancer who carry BRCA and other mutations.

The optimal management of esophageal and gastroesophageal junction cancers remains contentious on a number of issues, including the optimal extent of lymph node resection performed at surgery.

Patients with long duration of inflammatory bowel disease and primary sclerosing cholangitis had an increased risk for development of cholangiocarcinoma, according to data from a retrospective review.

Combination therapy with sulindac and erlotinib reduced duodenal polyp burden in patients with familial adenomatous polyposis, according to the results of a double blind, randomized, placebo-controlled trial.